Domiciliary nebulised bronchodilator therapy in chronic obstructive pulmonary disease

C. Smyth, I. Ryland, J. Earis

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Regular nebulised bronchodilator therapy in the home is commonly prescribed for patients with chronic obstructive pulmonary disease (COPD). If this therapy is administered inappropriately it exposes patients to potential side effects and has considerable financial cost to the health service. In a recent large audit in Liverpool we found that many patients with mild to moderate disease have obtained nebulisers from a variety of different sources including hospitals, primary care physicians, relatives and even the small advertisements of local papers.1 In this review the current rationale and recommendations for domiciliary nebulised bronchodilator therapy for patients with COPD are discussed. In 1997, the British Thoracic Society published guidelines concerning the supply, use and maintenance of nebuliser-compressor systems for chronic therapy in the patient's home.2 It was recommended that in the management of patients with COPD, such treatment should be reserved for only the minority in whom bronchodilator therapy, when effectively administered at a high dose from a handheld inhaler device, fails to provide adequate symptomatic relief. These guidelines also state that nebuliser provision should be made only after a full assessment by either a respiratory physician or trained hospital specialist or general practitioner.
Original languageEnglish
Pages (from-to)103-105
JournalPrimary Care Respiratory Journal
Volume10
Issue number4
Publication statusPublished - 2001

Fingerprint

Bronchodilator Agents
Lung Diseases
Nebulizers and Vaporizers
Chronic Obstructive Pulmonary Disease
Therapeutics
Guidelines
Primary Care Physicians
General Practitioners
Health Services
Maintenance
Physicians
Costs and Cost Analysis
Equipment and Supplies

Cite this

@article{9f0a539f1e9d4ded98fb441f025b8143,
title = "Domiciliary nebulised bronchodilator therapy in chronic obstructive pulmonary disease",
abstract = "Regular nebulised bronchodilator therapy in the home is commonly prescribed for patients with chronic obstructive pulmonary disease (COPD). If this therapy is administered inappropriately it exposes patients to potential side effects and has considerable financial cost to the health service. In a recent large audit in Liverpool we found that many patients with mild to moderate disease have obtained nebulisers from a variety of different sources including hospitals, primary care physicians, relatives and even the small advertisements of local papers.1 In this review the current rationale and recommendations for domiciliary nebulised bronchodilator therapy for patients with COPD are discussed. In 1997, the British Thoracic Society published guidelines concerning the supply, use and maintenance of nebuliser-compressor systems for chronic therapy in the patient's home.2 It was recommended that in the management of patients with COPD, such treatment should be reserved for only the minority in whom bronchodilator therapy, when effectively administered at a high dose from a handheld inhaler device, fails to provide adequate symptomatic relief. These guidelines also state that nebuliser provision should be made only after a full assessment by either a respiratory physician or trained hospital specialist or general practitioner.",
author = "C. Smyth and I. Ryland and J. Earis",
year = "2001",
language = "English",
volume = "10",
pages = "103--105",
journal = "Primary Care Respiratory Journal",
issn = "1471-4418",
publisher = "Primary Care Respiratory Society UK",
number = "4",

}

Domiciliary nebulised bronchodilator therapy in chronic obstructive pulmonary disease. / Smyth, C.; Ryland, I.; Earis, J.

In: Primary Care Respiratory Journal, Vol. 10, No. 4, 2001, p. 103-105.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Domiciliary nebulised bronchodilator therapy in chronic obstructive pulmonary disease

AU - Smyth, C.

AU - Ryland, I.

AU - Earis, J.

PY - 2001

Y1 - 2001

N2 - Regular nebulised bronchodilator therapy in the home is commonly prescribed for patients with chronic obstructive pulmonary disease (COPD). If this therapy is administered inappropriately it exposes patients to potential side effects and has considerable financial cost to the health service. In a recent large audit in Liverpool we found that many patients with mild to moderate disease have obtained nebulisers from a variety of different sources including hospitals, primary care physicians, relatives and even the small advertisements of local papers.1 In this review the current rationale and recommendations for domiciliary nebulised bronchodilator therapy for patients with COPD are discussed. In 1997, the British Thoracic Society published guidelines concerning the supply, use and maintenance of nebuliser-compressor systems for chronic therapy in the patient's home.2 It was recommended that in the management of patients with COPD, such treatment should be reserved for only the minority in whom bronchodilator therapy, when effectively administered at a high dose from a handheld inhaler device, fails to provide adequate symptomatic relief. These guidelines also state that nebuliser provision should be made only after a full assessment by either a respiratory physician or trained hospital specialist or general practitioner.

AB - Regular nebulised bronchodilator therapy in the home is commonly prescribed for patients with chronic obstructive pulmonary disease (COPD). If this therapy is administered inappropriately it exposes patients to potential side effects and has considerable financial cost to the health service. In a recent large audit in Liverpool we found that many patients with mild to moderate disease have obtained nebulisers from a variety of different sources including hospitals, primary care physicians, relatives and even the small advertisements of local papers.1 In this review the current rationale and recommendations for domiciliary nebulised bronchodilator therapy for patients with COPD are discussed. In 1997, the British Thoracic Society published guidelines concerning the supply, use and maintenance of nebuliser-compressor systems for chronic therapy in the patient's home.2 It was recommended that in the management of patients with COPD, such treatment should be reserved for only the minority in whom bronchodilator therapy, when effectively administered at a high dose from a handheld inhaler device, fails to provide adequate symptomatic relief. These guidelines also state that nebuliser provision should be made only after a full assessment by either a respiratory physician or trained hospital specialist or general practitioner.

M3 - Article

VL - 10

SP - 103

EP - 105

JO - Primary Care Respiratory Journal

JF - Primary Care Respiratory Journal

SN - 1471-4418

IS - 4

ER -